Search Results

February 28, 2025

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. Recommendation supported by results from CEPHEUS, the fifth Phase 3 study of daratumumab to demonstrate improved progression free survival in the frontline setting.1,2,3,4

An image of colorectal cancer (left) and colitis (right), which can raise your risk of developing colorectal cancer

Health & wellness

February 27, 2025

5 things we now know about colorectal cancer

Surprising new research suggests that people younger than 50 are getting diagnosed with the disease at record rates. For National Colorectal Cancer Awareness Month, find out how to protect yourself—no matter your age.

Healthcare professional preparing an IV infusion for a patient undergoing CAR-T cell therapy, a form of advanced cell therapy treatment

Innovation

February 26, 2025

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.

People from J&J Singapore celebrating 50 years

Our heritage

February 21, 2025

50 years of meeting healthcare needs in Singapore

February 21, 2025

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction

February 20, 2025

Johnson & Johnson MedTech Celebrates Inaugural National Heart Recovery Awareness Day

Impella patients share stories of heart recovery at reunions, events across the country Launch of Boston’s first hands-only CPR kiosk with American Heart Association

Innovation

February 19, 2025

“The surgical devices I design for Johnson & Johnson can help speed healing and save lives”

Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.

February 14, 2025

Johnson & Johnson to Resume U.S. VARIPULSE™ Cases

Investigation found that VARIPULSE™ devices operate as intended Cases being performed in U.S. External Evaluation to resume and Instructions for Use to be updated

Microscopic view of metastatic cancer cells stained for histological analysis, showing tumor cell clusters

Innovative Medicine

February 14, 2025

What is metastatic cancer?

The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.

February 13, 2025

New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions

Search Results

No Results

Recently Viewed

Search Results